ARD-3100/3150 (Pulmaquin®, Lipoquin®)


Other Applications

Scientific Publications

Events and Presentations



ARD-1600 - (Nicotine) Tobacco Smoking Cessation Therapy

According to the National Center for Health Statistics (“NCHS”), 21% of the U.S. population age 18 and above currently smoke cigarettes. The World Health Organization estimates that 650 million people worldwide are smokers, which results in a health cost equivalent to $200 billion, $75 billion in the U.S. alone. Further, the NCHS indicates that nicotine dependence is the most common form of chemical dependence in this country. As a result, quitting tobacco use is difficult and often requires multiple attempts, as users often relapse because of withdrawal symptoms. Our goal is to develop an inhaled nicotine product that would address effectively the acute craving for cigarettes and, through gradual reduction of the peak nicotine levels, wean-off the patients from cigarette smoking and from the nicotine addiction.


The initial laboratory work on this program was partly funded under grants from the National Institute of Health. We have recently completed the first human clinical trial delivering aqueous solutions of nicotine using the palm-size AERx Essence® system. Our randomized, open-label, single-site Phase 1 trial evaluated arterial plasma pharmacokinetics and subjective acute cigarette craving when one of three nicotine doses was administered to 18 adult male smokers. Blood levels of nicotine rose much more rapidly following a single-breath inhalation compared to published data on other approved nicotine delivery systems. Cravings for cigarettes were measured on a scale from 0-10 before and after dosing for up to four hours. Prior to dosing, mean craving scores were 5.5, 5.5 and 5.0, respectively, for the three doses. At five minutes following inhalation of the nicotine solution through the AERx Essence device, craving scores were reduced to 1.3, 1.7 and 1.3, respectively, and did not return to pre-dose baseline during the four hours of monitoring. Nearly all subjects reported an acute reduction in craving or an absence of craving immediately following dosing. No serious adverse reactions were reported in the study.

We believe these results provide the foundation for further research with the AERx Essence device as a means toward smoking cessation. We are currently seeking collaborations with government and non-government organizations to further develop this product.



Scientific Publication
Cipolla D and Gonda I. Inhaled Nicotine Replacement Therapy. Asian J Pharm Sci. 2015;10(6)472-480.

Gonda, I. et al.: “ Smoking Cessation Approach Via Deep Lung Delivery of ‘Clean’ Nicotine”, PR Byron, J Peart, JD Suman and PM Young (eds), Respiratory Drug Delivery Europe 2009, book 1, pp.57-62

Cipolla D, et al. Development of an Inhaled AERx Essence Nicotine Product for Smoking Cessation. In: Respiratory Drug Delivery 2008. 2008:365-369. Editors, Richard N. Dalby, Peter R. Byron, Joanne Peart, Julie D. Suman, Stephen J. Farr. Published by Davis Healthcare Int’l Publishing LLC, River Grove, IL. Scottsdale, AZ, May 11-15, 2008. 



©2019 Aradigm Corporation. All Rights Reserved.